Chemotherapy for androgen-independent prostate cancerPETRYLAK, Daniel P.Seminars in urologic oncology. 2002, Vol 20, Num 3, pp 31-35, issn 1081-0943, SUP1Conference Paper

The coming revolution in the treatment of prostate cancer patientsPETRYLAK, Daniel P.Seminars in urologic oncology. 2002, Vol 20, Num 3, issn 1081-0943, 37 p., SUP1Conference Proceedings

Chemotherapy for androgen-independent prostate cancerPETRYLAK, Daniel P.World journal of urology (Print). 2005, Vol 23, Num 1, pp 10-13, issn 0724-4983, 4 p.Article

Chemotherapy for the treatment of hormone-refractory prostate cancerPETRYLAK, Daniel P.European urology. Supplement. 2002, Vol 1, Num 2, pp 15-23, issn 1569-9056, 9 p.Article

Perioperative chemotherapy for bladder cancerSONPAVDE, Guru; PETRYLAK, Daniel P.Critical reviews in oncology/hematology. 2006, Vol 57, Num 2, pp 133-144, issn 1040-8428, 12 p.Article

The case for early chemotherapy for the treatment of metastatic diseaseLUCAS, Aimee; PETRYLAK, Daniel P.The Journal of urology. 2006, Vol 176, Num 6, issn 0022-5347, S72-S75, 2Article

Hormonal therapy of prostate cancerDEBRUYNE, Frans.Seminars in urologic oncology. 2002, Vol 20, Num 3, pp 4-9, issn 1081-0943, SUP1Conference Paper

New Therapeutic Challenges in Advanced Bladder CancerBELLMUNT, Joaquim; PETRYLAK, Daniel P.Seminars in oncology. 2012, Vol 39, Num 5, pp 598-607, issn 0093-7754, 10 p.Article

Future directions in the treatment of androgen- independent prostate cancerPETRYLAK, Daniel P.Urology (Ridgewood, NJ). 2005, Vol 65, Num 6A, pp 8-12, issn 0090-4295, 5 p.Conference Paper

Management of high-risk localized prostate cancer: the integration of local and systemic therapy approaches : The high-risk prostate cancer patientSYED, Samira; PETRYLAK, Daniel P; THOMPSON, Ian M et al.Urologic oncology. 2003, Vol 21, Num 3, pp 235-243, issn 1078-1439, 9 p.Article

Therapeutic considerations for patients with high-risk, nonmetastatic, prostate cancerEISENBERGER, Mario A.Seminars in urologic oncology. 2002, Vol 20, Num 3, pp 19-23, issn 1081-0943, SUP1Conference Paper

The current role of chemotherapy in metastatic hormone-refractory prostate cancer. DiscussionPETRYLAK, Daniel P; PETRYLAK, Daniel P et al.SMITH, Matthew R; PETRYLAK, Daniel P; PETRYLAK, Daniel P et al.Urology (Ridgewood, NJ). 2005, Vol 65, Num 5A, pp 3-8, issn 0090-4295, 6 p., SUPConference Paper

Secondary hormonal manipulation of prostate cancerSMALL, Eric J; HARRIS, Katherine A.Seminars in urologic oncology. 2002, Vol 20, Num 3, pp 24-30, issn 1081-0943, SUP1Conference Paper

Role of quality of life in men with metastatic hormone-refractory prostate cancer : How does atrasentan influence quality of life?CELLA, David; PETRYLAK, Daniel P; FISHMAN, Mayer et al.European urology. 2006, Vol 49, Num 5, pp 781-789, issn 0302-2838, 9 p.Article

The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cellsDREW, Lisa; FINE, Robert L; DO, Tamara N et al.Clinical cancer research. 2002, Vol 8, Num 12, pp 3922-3932, issn 1078-0432, 11 p.Article

Relative Efficacy of Perioperative Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Adriamycin, and Cisplatin in the Management of Locally Advanced Urothelial Carcinoma of the BladderYESHCHINA, Olga; BADALATO, Gina M; WOSNITZER, Matthew S et al.Urology (Ridgewood, NJ). 2012, Vol 79, Num 2, pp 384-390, issn 0090-4295, 7 p.Article

Kinetics of Serum Androgen Normalization and Factors Associated With Testosterone Reserve After Limited Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer. CommentaryGULLEY, James L; ARAGON-CHING, Jeanny B; DAHUT, William L et al.The Journal of urology. 2008, Vol 180, Num 4, pp 1432-1437, issn 0022-5347, 6 p., 1Article

A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablationMOHILE, Supriya G; BYLOW, Kathryn; DALE, William et al.Cancer. 2007, Vol 109, Num 4, pp 802-810, issn 0008-543X, 9 p.Article

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer : A report from the ASCENT investigatorsBEER, Tomasz M; RYAN, Christopher W; CARDUCCI, Michael A et al.Journal of clinical oncology. 2007, Vol 25, Num 6, pp 669-674, issn 0732-183X, 6 p.Article

Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patientsLEE, Nancy; FAWAAZ, Rashid; OLSSON, Carl A et al.International journal of radiation oncology, biology, physics. 2000, Vol 48, Num 5, pp 1443-1446, issn 0360-3016Article

Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate CancerDE BONO, Johann S; PIULATS, Josep M; TAO WANG et al.Clinical cancer research (Print). 2014, Vol 20, Num 7, pp 1925-1934, issn 1078-0432, 10 p.Article

Role of Testosterone in Managing Advanced Prostate CancerROVE, Kyle O; DEBRUYNE, Frans M; DJAVAN, Bob et al.Urology (Ridgewood, NJ). 2012, Vol 80, Num 4, pp 754-762, issn 0090-4295, 9 p.Article

A Phase I Trial of Intravesical Nanoparticle Albumin-Bound Paclitaxel in the Treatment of Bacillus Calmette-Guérin Refractory Nonmuscle Invasive Bladder CancerMCKIERNAN, James M; BARLOW, Lamont J; LAUDANO, Melissa A et al.The Journal of urology. 2011, Vol 186, Num 2, pp 448-451, issn 0022-5347, 4 p.Article

Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy : A multi-institutional pilot studyKIBEL, Adam S; ROSENBAUM, Eli; COOKSON, Michael S et al.The Journal of urology. 2007, Vol 177, Num 5, pp 1777-1781, issn 0022-5347, 5 p.Article

Association of body mass index with response and survival in men with metastatic prostate cancer : Southwest oncology group trials 8894 and 9916. CommentaryMONTGOMERY, R. Bruce; GOLDMAN, Bryan; TANGEN, Catherine M et al.The Journal of urology. 2007, Vol 178, Num 5, pp 1946-1951, issn 0022-5347, 6 p.Article